结直肠癌中SP1的瘤内异质性表达及其临床意义

doi:10.6040/j.issn.1671-7554.0.2024.0212

摘要/Abstract

摘要： 目的探讨结直肠癌(colorectal cancer, CRC)中特异蛋白1(specificity protein 1, SP1)表达的瘤内异质性(intratumor heterogeneity, ITH)及其临床意义。方法收集CRC临床标本,采用免疫组化EnVision法检测SP1蛋白的表达水平及模式,明确SP1蛋白表达的ITH特征,定义SP1蛋白的ITH水平,并分析SP1蛋白ITH水平与CRC患者临床病理特征及预后的关系。结果在CRC中SP1蛋白呈典型的ITH表达特征,其ITH水平与淋巴结转移(P<0.001)和TNM分期(P<0.001)相关。生存分析表明,SP1蛋白高ITH患者的总生存期(overall survival, OS)显著低于SP1蛋白低ITH患者(61.25% vs 81.82%),差异有统计学意义(P=0.004)。单因素和多因素Cox回归分析显示,SP1蛋白高ITH是CRC患者不良OS(HR=2.680,P=0.017)的独立预测因子。结论 CRC中SP1蛋白的表达具有显著的ITH特征,并首次定义了SP1 ITH水平的量化标准,证实SP1蛋白高ITH与CRC进展及不良预后显著相关。

关键词: 结直肠癌, SP1蛋白, 瘤内异质性, 免疫组织化学, 预后

Abstract: Objective To investigate the intratumor heterogeneity(ITH)of specificity protein 1(SP1)protein expression in colorectal cancer(CRC)and its clinical significance. Methods Clinical specimens of CRC were collected. The expression level and pattern of SP1 protein were detected by immunohistochemical EnVision method. The ITH characteristics of SP1 protein expression were identified, and the ITH level of SP1 protein was defined. The relationship between ITH level of SP1 protein and clinicopathological characteristics and prognosis of CRC patients was analyzed. Results SP1 protein showed typical ITH expression in CRC. The ITH level of SP1 protein was associated with lymph node metastasis(P<0.001)and TNM stage(P<0.001). Survival analysis showed that the overall survival(OS)of patients with high ITH level of SP1 protein was significantly lower than that with low ITH level(61.25% vs 81.82%, P=0.004). Univariate and multivariate Cox regression analyses showed that high SP1 protein ITH was an independent predictor of poor OS in CRC patients(HR=2.680, P=0.017). Conclusion The expression of SP1 protein in CRC has significant ITH characteristics, and defines the quantitative criteria of SP1 ITH level for the first time. It is demonstrated that a high ITH level of SP1 protein is significantly associated with CRC progression and poor prognosis.

Key words: Colorectal cancer, SP1 protein, Intratumor heterogeneity, Immunohistochemistry, Prognosis

中图分类号:

R735.3

魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.

WEI Yanruoxue, LI Ziqi, LIU Chuncheng, LIU Xiaohan, ZHAO Ran, LIU Yukun. Intratumor heterogeneity of SP1 expression in colorectal cancer and its clinical significance[J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 89-94.

参考文献

[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2] Lu Z, Chen Y, Liu D, et al. The landscape of cancer research and cancer care in China [J]. Nat Med, 2023, 29(12): 3022-3032.
[3] Du L, Cheng Q, Zheng H, et al. Targeting stemness of cancer stem cells to fight colorectal cancers [J]. Semin Cancer Biol, 2022, 82: 150-161. doi: 10.1016/j.semcancer.
[4] Jiang M, Jin S, Han J, et al. Detection and clinical significance of circulating tumor cells in colorectal cancer [J]. Biomark Res, 2021, 9(1): 85. doi: 10.1186/s40364-021-00326-4.
[5] Pietropaolo G, Scarno G, Stabile H, et al. NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data [J]. Mol Aspects Med, 2021, 80: 100967. doi: 10.1016/j.mam.2021.100967.
[6] Crucitta S, Cucchiara F, Mathijssen R, et al. Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours [J]. Cancer Treat Rev, 2022, 104: 102340. doi: 10.1016/j.ctrv.2022.102340.
[7] Mauri G, Vitiello PP, Sogari A, et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer [J]. Br J Cancer, 2022, 127(3): 394-407.
[8] Al Zein M, Boukhdoud M, Shammaa H, et al. Immunotherapy and immunoevasion of colorectal cancer [J]. Drug Discov Today, 2023, 28(9): 103669. doi: 10.1016/j.drudis.2023.103669.
[9] Zhang GP, Xie ZL, Jiang J, et al. Mechanical confinement promotes heat resistance of hepatocellular carcinoma via SP1/IL4I1/AHR axis [J]. Cell Rep Med, 2023, 4(8): 101128. doi: 10.1016/j.xcrm.2023.101128.
[10] Zhang M, Kan D, Zhang B, et al. P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC [J]. J Exp Clin Cancer Res, 2023, 42(1): 215. doi: 10.1186/s13046-023-02777-z.
[11] Zhao G, Yuan H, Li Q, et al. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2 [J]. Signal Transduct Target Ther, 2022, 7(1): 275. doi: 10.1038/s41392-022-01096-7.
[12] Zhu Z, Guo Y, Liu Y, et al. ELK4 Promotes colorectal cancer progression by activating the neoangiogenic factor LRG1 in a noncanonical SP1/3-dependent manner [J]. Adv Sci(Weinh), 2023, 10(32): e2303378. doi: 10.1002/advs.202303378.
[13] Fosso E, Leo M, Muccillo L, et al. Quercetins dual mode of action to counteract the Sp1-miR-27a axis in colorectal cancer cells [J]. Antioxidants(Basel), 2023, 12(8): 1547. doi: 10.3390/antiox12081547.
[14] Tang T, Fang D, Ji Z, et al. Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells [J]. Cell Oncol(Dordr), 2023. doi: 10.1007/s13402-023-00887-6.
[15] Liu J, Zhan W, Chen G, et al. SP1-induced PROX1-AS1 contributes to tumor progression by regulating miR-326/FBXL20 axis in colorectal cancer [J]. Cell Signal, 2023, 101: 110503. doi: 10.1016/j.cellsig.2022.110503.
[16] Kahn AM, Golestani R, Harigopal M, et al. Intratumor spatial heterogeneity in programmed death-ligand 1(PD-L1)protein expression in early-stage breast cancer [J]. Breast Cancer Res Treat, 2023, 201(2): 289-298.
[17] Ge LP, Jin X, Ma D, et al. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer [J]. Cell Res, 2024, 34(1): 58-75.
[18] Geng K, Merino LG, Veiga RG, et al. Intrinsic deletion at 10q23.31, including the PTEN gene locus, is aggravated upon CRISPR-Cas9-mediated genome engineering in HAP1 cells mimicking cancer profiles [J]. Life Sci Alliance, 2023, 7(2): e202302128. doi: 10.26508/lsa.202302128.
[19] Tornesello ML, Cerasuolo A, Starita N, et al. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations [J]. Front Cell Dev Biol, 2023, 11: 1286683. doi: 10.3389/fcell.2023.1286683.
[20] Enikeeva K, Rafikova G, Sharifyanova Y, et al. Epigenetics as a key factor in prostate cancer [J]. Adv Biol(Weinh), 2024, 20: e2300520. doi: 10.1002/adbi.202300520.
[21] Gasperoni JG, Fuller JN, Darido C, et al. Grainyhead-like(Grhl)target genes in development and cancer [J]. Int J Mol Sci, 2022, 23(5): 2735. doi: 10.3390/ijms23052735.
[22] He W, Hong X, Chen G, et al. RNA modifications in gynecological cancer: current status and future directions [J]. Front Med(Lausanne), 2024, 11: 1314075. doi: 10.3389/fmed.2024.1314075.
[23] Su X, Lu R, Qu Y, et al. Diagnostic and therapeutic potentials of methyltransferase-like 3 in liver diseases [J]. Biomed Pharmacother, 2024, 172: 116157. doi: 10.1016/j.biopha.2024.116157.
[24] Peng N, Liu J, Hai S, et al. Role of post-translational modifications in colorectal cancer metastasis [J]. Cancers(Basel), 2024, 16(3): 652. doi: 10.3390/cancers16030652.
[25] Taylor BC, Sun X, Gonzalez-Ericsson PI, et al. NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple negative breast cancer [J]. Cancer Discov, 2024, 14(2): 290-307.
[26] Corpetti M, Müller C, Beltran H, et al. Prostate-specific membrane antigen-targeted therapies for prostate cancer: towards improving therapeutic outcomes [J]. Eur Urol, 2024, 85(3): 193-204.
[27] Wang Y, Zhou Y, Yang L, et al. Challenges coexist with opportunities: spatial heterogeneity expression of PD-L1 in cancer therapy [J]. Adv Sci(Weinh), 2024, 11(1): e2303175. doi: 10.1002/advs.202303175.
[28] Valenza C, Guidi L, Battaiotto E, et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers [J]. Trends Cancer, 2024, 10(2): 113-123.

相关文章 15

[1]	黄方康瑞吴春林. VEGFC、NF-κBp65及Survivin在鼻咽癌中的表达及临床意义[J]. 山东大学学报(医学版), 2209, 47(6): 83-.
[2]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[3]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[4]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[5]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[6]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[7]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[8]	王刚,徐鹏演,赵旭安,王海锋,葛苗苗,潘华峰,江志伟. ω-3多不饱和脂肪酸对腹腔镜结直肠癌术后迷走神经和肠功能恢复的影响[J]. 山东大学学报 (医学版), 2025, 63(2): 36-42.
[9]	崔倩倩,李金鹏,吴豫丹,侯志平,孙玮螺,崔盼盼,何培元. 粪便miRNA对结直肠进展期腺瘤无创筛查的临床价值[J]. 山东大学学报 (医学版), 2025, 63(2): 43-50.
[10]	常宇,胡云峰,王会丰,郭静,张跳,郝雅琴,刘雨. 阑尾切除术与结直肠癌发病风险关联的孟德尔随机化研究[J]. 山东大学学报 (医学版), 2025, 63(2): 77-83.
[11]	俞静,王刚,王烨,邵明月,潘华峰,葛苗苗,王海锋,江志伟. 基于I-FEED评分系统观察益气导滞方对结直肠癌术后胃肠功能恢复的影响[J]. 山东大学学报 (医学版), 2025, 63(12): 35-43.
[12]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[13]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[14]	郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[15]	王潇,孔文茹,崔伟亮,王姝麒. 羊角棉总生物碱增强氟尿嘧啶对结直肠癌化疗敏感性[J]. 山东大学学报 (医学版), 2024, 62(6): 30-37.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed